Shilpa Medicare growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+19.6%+13.6%
EBITDA+37.1%+62.0%
Net Income+211.0%—
EPS (adj.)+211.0%—
Total Assets+11.9%+8.5%
Total Equity+9.6%+13.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SHILPAMED₹935.60

Shilpa Medicare Ltd.

· Pharma & Health
₹ CrorePeersNATCOPHARMSPARCSTARRUBICONSUPRIYATHYROCAREVIYASHPARKHOSPSMcap ₹18,300 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+19.6+13.6
EBITDA+37.1+62.0
Net Income+211.0—
EPS (adj.)+211.0—
Total Assets+11.9+8.5
Total Equity+9.6+13.5
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.